Moteur de recherche d’entreprises européennes
Financement de l’UE (7 928 633 €) : Validation des modifications de la α-synucléine dans l’évolution de la maladie de Parkinson Hor01/11/2024 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
Validation des modifications de la α-synucléine dans l’évolution de la maladie de Parkinson
Parkinson's disease (PD) presents a complex challenge due to its progressive neurodegenerative nature, affecting various body systems. Despite decades of research, understanding its onset and progression remains unclear, complicating early diagnosis and treatment. Recent advancements in PD physiopathology suggest promising treatments to slow disease progression, yet reversing cellular degeneration remains elusive. With novel therapies emerging, the need for early detection tools is urgent. However, validated biomarkers for PD diagnosis are lacking, relying on subjective scales like Hoehn and Yahr or costly medical imaging techniques. The accumulation of misfolded α-Synuclein (α-Syn) proteins in PD pathology has sparked interest, but defining diagnostic roles requires further investigation. Recent findings of α-Syn in neuronal-derived extracellular vesicles (NDEVs) from PD patients suggest a potential for novel diagnostic methods. Our proposed project, VαMPiRE, aims to conduct a longitudinal study involving 600 PD patients and 600 healthy subjects to explore α-Syn isoforms and related biomarkers in NDEVs for early PD detection. We plan to develop and validate an innovative in-vitro diagnostic (IVD) test capable of detecting PD's earliest stages and estimating disease prognosis and progression. Utilizing AI models to generate data analysis algorithms and collaboration with leading analytical laboratories and IVD manufacturers, we aim to ensure the reliability and feasibility of the developed prototype. Through consortium efforts, we envision licensing the generated intellectual property to drive the commercialization of our results. This can improve early screening of 270,000 new cases of PD could be detected early and improve the disease management of 9.4 M people currently diagnosed of PD and avoid losing a total of 5.8 million disability adjusted life years (DALYs) by 2028 leading also the development of better treatments.
| University of Newcastle | ? |
| Acondicionamiento Tarrasense Associacion | 449 074 € |
| Almawave S.p.A. | 434 250 € |
| Aristotelio Panepistimio Thessalonikis | 229 500 € |
| Asociacion Parkinson Madrid | 394 625 € |
| Casa Di Cura Igea S.p.A. | 958 887 € |
| Fondazione European Brain Researchinstitute Rita Levi | 1 126 156 € |
| Institut National de la Sante et de la Recherche Medicale | 703 094 € |
| Instytut Psychiatrii i Neurologii | 242 000 € |
| Linkcare Health Services SL | 1 619 063 € |
| Spitalul Universitar de Urgenta Bucuresti | 17 937,50 € |
| Synlab Italia Srl | 533 375 € |
| Universidad de Oviedo | 213 426 € |
| Universita Degli Studi Di Roma LA Sapienza | 202 563 € |
| Universitaetsmedizin Goettingen - Georg-August-Universitaet Goettingen - Stiftung Oeffentlichen Rechts | 464 675 € |
| Universitat Autonoma de Barcelona | 340 009 € |
https://cordis.europa.eu/project/id/101156370
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Université de Newcastle, Mosman Park, Australie.
